A breakthrough molecular strategy
to enrich multiple disease-related rare genetic DNA variants in a simple, fast, and robust assay will revolutionize individualized diagnosis and treatments.

NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world’s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capability in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.

Global Founders

Peng Yin, Ph.D.

Peng Yin, Ph.D., is Professor of Systems Biology at Harvard Medical School and Core Faculty member at Wyss Institute. He is a leading expert in DNA nanotechnology and biotechnology. He is also co-founder of Ultivue, Inc.

David Yu Zhang, Ph.D.

David Zhang, Ph.D., is the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. He is a leading expert in molecular diagnostics and DNA biotechnology, and maintains active collaborations with multiple biotech companies.

Victor Chenyang Shi, Ph.D.

Victor Shi, Ph.D., is a seasoned business executive, entrepreneur, and investor in diagnostics and biotech industry. He was the Founding President of Qiagen Asia Pacific and a former Professor at National University of Singapore.


NuProbe technology utilizes DNA toehold probe systems based on the fundamental engineering principle of molecular competition and precisely balanced thermodynamics and its application to PCR rare allele detection.

Toehold probe design achieves near optimal specificity and is robust against environmental variation. Toehold probe designs improved qPCR mutation detection by 100 fold with sensitivity down to 0.01% and multiplexing capability of 10 (and potentially 100) multiplexed reactions with hundreds mutations in the same test tube, enabling non-invasive early stage cancer cell-free DNA detection in blood plasma. We validated the technology with US patient sample, and is in the process of conducting preliminary clinical trial in China.


Nuprobe’s toehold probe designs improved qPCR mutation detection by 100 fold with sensitivity down to 0.01%with 10 validated multiplexing capabilities. This technology is verified with blood plasma samples from cancer patients.


NuProbe’s proprietary toehold probe technology provides an economic Sample-In Answer-Out (SIAO) solution in which cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations are integrated.


NuProbe’s unparalleled targeted variant enrichment probe set enables much greater sensitivity and higher sample throughput for next generation sequencing (NGS).


Technology developer

Requires Ph.D. in bioengineering, genomics, molecular diagnostics, or relevant fields.  Will be developing novel workflows and reagents for NGS, based on toehold probe and BDA technology.

Assay developer

Requires Ph.D. in bioengineering, molecular diagnostics, or relevant fields.  Will be developing and validating oncology tests, using BDA technology, with aim for FDA or CFDA submission.

Manufacturing technician

Requires B.S. in bioengineering, biology, chemistry, mechanical engineering, or relevant fields. Will be working with technology and assay developers to prototype instrumentation and reagents, process clinical samples, and prepare and package products.

Business development lead

Requires 3+ years experience in business development, sales, or marketing in the field of molecular diagnostics, nucleic acid assays, or NGS.  Will be working to evaluate new RUO and clinical markets, as well as to identify KOL in oncology for piloting NuProbe products.